



Vertex Pharmaceuticals Incorporated  
130 Waverly Street • Cambridge, MA 02139-4242  
Tel. 617.444.6100 • Fax 617.444.6483  
<http://www.vrtx.com>

**RECEIVED**  
**CENTRAL FAX CENTER**

**DEC 04 2006**

## FAX TRANSMISSION

|                     |   |
|---------------------|---|
| To                  | USPTO                                     |
| Examiner            | Deepak Rao                                |
| Group Art Unit      | 1624                                      |
| From                | Karen E. Brown                            |
| Date                | December 4, 2006                          |
| Application No.     | 10/779,532                                |
| Attorney Docket No. | VPI/99-109 DIV US<br>Petition for Revival |
| Total Pages         | 11  |

### Message or Comment

If any problems occur with this fax transmittal, please call (617) 444-6168 immediately.

**RECEIVED  
CENTRAL FAX CENTER  
DEC 04 2006**

Attorney Docket No.: VPI/99-109 DIV US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/779,532  
Confirmation No.: 5593  
Filing Date: February 13, 2004  
Examiner: Deepak R. Rao  
Group Art Unit: 1624  
Applicants: Jeremy Green et al.  
For: **INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)  
AND OTHER PROTEIN KINASES**

**Certificate of Facsimile Transmission Under 37 CFR §1.8**

I hereby certify that this correspondence and any documents referred to as attached hereto are being facsimile transmitted to the United States Patent and Trademark Office on December 4, 2006.

Lisa M. Romano

*Lisa M. Romano*

Signature

December 4, 2006  
Cambridge, Massachusetts

Mail Stop Petition  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Sir:

Transmitted herewith: [X] a Petition for Revival of an Application for Patent Abandoned Unintentionally Under 37 C.F.C. § 1.137(b); [X] Part B - Fee Transmittal (in duplicate); to be filed in the above-identified patent application.

Applicants: Jeremy Green et al.  
Application No. 10/779,532

RECEIVED  
CENTRAL FAX CENTER  
DEC 04 2006

FEE FOR ADDITIONAL CLAIMS

- ☒ A fee for additional claims is not required.
- ☐ A fee for additional claims is required.
- ☐ A check in the amount of \$\_\_\_ in payment of the filing fee is transmitted herewith.
- ☐ Please charge \$\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

EXTENSION FEE

- ☐ The following extension is applicable to the Response filed herewith; ☐ \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); ☐ \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); ☐ \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- ☐ A check in the amount of ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00 in payment of the extension fee is transmitted herewith.
- ☐ Please charge the extension fee in the amount of ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

- ☒ Please charge \$1,500.00 to Deposit Account No. 50-0725 in payment of Petition to revive unintentionally abandoned application (37 C.F.R. § 1.17(m)). A duplicate copy of this transmittal letter is transmitted herewith.

**RECEIVED**  
**CENTRAL FAX CENTER**  
**DEC 04 2006**

Applicants: Jeremy Green et al.  
Application No. 10/779,532

Respectfully submitted,



Karen E. Brown, Reg. No. 43,866

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483  
Customer No. 27916

**RECEIVED  
CENTRAL FAX CENTER  
DEC 04 2006**

Attorney Docket No. VPI/99-109 DIV US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/779,532  
Confirmation No.: 5593  
Filing Date: February 13, 2004  
Examiner: Deepak R. Rao  
Group Art Unit: 1624  
Applicants: Jeremy Green et al.  
For: INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)  
AND OTHER PROTEIN KINASES

December 4, 2006  
Cambridge, Massachusetts

Mail Stop Petition  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT  
ABANDONED UNINTENTIONALLY UNDER 37 C.F.R. § 1.137(b)**

Sir:

Pursuant to 37 C.F.R. § 1.137(b), applicants hereby petition for revival of the above-identified patent application.

This application unintentionally became abandoned as of November 30, 2006, because of applicants' lack of response to the August 30, 2006 Notice of Allowance and Fees Due.

As required by 37 C.F.R. § 1.137(b), this petition is accompanied by:

12/06/2006 AHONDAF1 00000081 500725 10779532

01 FC:1453 1500.00 DA

RECEIVED  
CENTRAL FAX CENTER  
DEC 04 2006

Attorney Docket No. VPI/99-109 DIV US


- (1) The Part B - Fee Transmittal form and an authorization to pay the corresponding issue and publication fees; and
- (2) An authorization to pay the petition fee set forth in 37 C.F.R. § 1.17(m).

As further required by 37 C.F.R. § 1.137(b), applicants hereby state that the entire delay in filing the required response, from the November 30, 2006 due date until the filing of this petition was unintentional.

Pursuant to 37 C.F.R. §§ 1.137(c) and (d), this petition is not accompanied by a terminal disclaimer because the above-identified application is a utility application filed after June 8, 1995.

Applicants respectfully request that this petition be granted and the above-identified patent application be revived. Early and favorable consideration of this petition is respectfully requested.

Respectfully submitted,



Karen E. Brown

Reg. No. 43,866

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483